Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
about
Ductal approaches to assessment and management of women at high risk for developing breast cancerCharacterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancerCancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation statusBRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North AfricanPancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parametersHereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamicsVariation in breast cancer risk in BRCA1 and BRCA2 mutation carriersPrevalence of the most frequent BRCA1 mutations in Polish populationExamining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model"Are you at risk for hereditary breast cancer?": development of a personal risk assessment tool for hereditary breast and ovarian cancer.Twenty questions in genetic medicine--an assessment of World Wide Web databases for genetics information at the point of care.Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.A Resident's Perspective of Ovarian Cancer.Hereditary pancreatic cancer: related syndromes and clinical perspective.Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Clinical management of hereditary breast cancer syndromes.Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.Hereditary ovarian cancer: not only BRCA 1 and 2 genes.Clinical management of BRCA1 and BRCA2 mutation carriers.Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.Breast cancer risk among male BRCA1 and BRCA2 mutation carriersCancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianHereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.Genotype in BRCA-associated breast cancersHereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian populationHereditary pancreatic and hepatobiliary cancersBrca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent.The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancersAssessing breast cancer risk: genetic factors are not the whole story.Genetic factors and colorectal cancer in Ashkenazi Jews.Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiencesPrevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective
P2860
Q24794407-C4CE962C-DC93-4FDF-B53E-8493CC75D5B6Q24796063-B87BB049-0C10-4948-B9D2-B79F2A05F24AQ24802534-4162A53F-39AA-4EF8-9A71-C50504550AAEQ27002334-C360D134-F70F-4339-B163-73A4B2C5DB12Q27022231-209056C1-0141-48F4-852D-046D9B811D1CQ28085485-AF62E010-C9A5-40EC-BA1A-F0B2C5E29783Q28383242-937AB87F-5ABA-4136-82AA-690157C40E0DQ28386156-1A0E71EB-DA82-4897-A234-A0F51F6F45D4Q28390186-A33FB3C5-8869-40C9-838B-03D7FDF61C25Q28390826-D371FFBD-8ADE-4791-B8DB-ECC617D15025Q30445357-4FB61F2A-A731-45FD-8193-7537929AB3E3Q30483973-8C7F16B6-A7B3-4913-BA85-696A66D15188Q33246295-FAFDA66D-EE92-4CDC-B902-00042D2578EEQ33416772-BB7538F3-73EA-4091-BA13-178CBD5E398BQ33687535-134596D0-A0E8-4B98-9D62-08021A49BD50Q33723561-8D63829E-3134-4794-8AC7-EAEE08FFA400Q33850471-BBBE71E7-CA3B-4771-AB70-06B7C7B17074Q33851085-BB4FAA6E-1A43-4069-A0F8-7083ECF8B5E2Q33896012-EE99EE52-FF94-425C-9C45-727E423B0278Q34121226-CC480F05-7684-4F4E-A15A-D859F00948A6Q34167563-F6EFCB42-9673-48A3-998D-2C0C0A715A2BQ34358066-97DF27BB-DE04-42E4-82BE-E2646C0FDF52Q34480707-B75A5229-86F1-44AB-BF37-EB12292414BEQ34568554-EF46D87A-DC7A-4CB8-BAE2-0822C0691AA5Q34698278-2F9A90BE-07E4-4808-83DD-1C461E7A559CQ34718829-B3FD7BD0-FD7D-442A-9260-882F05DC0937Q34945185-132DDFB9-F544-45D1-9527-F0F6A3A281E0Q34977063-9C036696-D0B6-4269-A5FA-5D3475C934B0Q35006713-5F666873-6A8A-4C10-9023-4A5695486A5DQ35624773-AD00BAD8-35BB-4315-A583-90CD28D1831DQ35645650-C113CBC5-5C4A-43CC-81E8-DA9372507609Q35692230-325FA9D6-3D0E-4F75-8C16-A194E133C11BQ35815854-E2731A21-9D3E-4CB4-91DD-AB5DD18C8502Q35906685-3A4BBC6A-9FF0-417E-BEC9-02EA3843568DQ35930932-E0010E81-B2AD-4839-9D39-220976ACE7DEQ35934035-BAD0940B-F133-461B-9389-AF30B97B1103Q35951280-D5D8F28A-B318-4D94-B674-1E63CD7AE9EDQ36070055-112DF7D7-0A1F-411C-A3A7-EFF6BDEB2FE6Q36166792-6F494073-85D1-4DA2-B4ED-C434C38E2EA9Q36322846-FF99C614-B9DE-4916-9594-9EAF24091901
P2860
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
description
article
@en
im September 2002 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2002
@uk
name
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@en
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@nl
type
label
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@en
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@nl
prefLabel
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@en
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
@nl
P2093
P356
P1476
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program
@en
P2093
Barbara L Weber
Jill E Stopfer
Kathleen A Calzone
Marcia S Brose
Timothy R Rebbeck
P304
P356
10.1093/JNCI/94.18.1365
P407
P577
2002-09-01T00:00:00Z